Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

COMy 2021 | Updates in CAR-T therapy for myeloma at COMy 2021

Arnon Nagler • 10 May 2021
COMy 2021
Multiple Myeloma Antibodies Belantamab mafodotin CAR-T Ciltacabtagene autoleucel Idecabtagene vicleucel Selinexor

Arnon Nagler, MD, Chaim Sheba Medical Center, Tel-Aviv, Israel, presents the key talking points in CAR T-cell therapy for the treatment of multiple myeloma. Prof. Nagler discusses how CAR-T therapy is achieving unprecedented results for advanced myeloma, with the additional benefit of low toxicity. Questions remain in the field, with research ongoing into optimization strategies and addressing resistance development to common CAR-T targets. This interview took place during the 7th World Congress on Controversies in Multiple Myeloma (COMy), 2021.

More from Arnon Nagler

2:25
Optimizing haplo-SCT for the treatment of AML
Arnon Nagler • 16 Apr 2024
1:21
Trends in alloSCT for good-risk AML: a longitudinal study
Arnon Nagler • 9 Dec 2023
2:15
GvHD prophylaxis post-alloSCT: PTCy versus ATG
Arnon Nagler • 9 Dec 2023
2:13
Haploidentical SCT for the treatment of secondary AML
Arnon Nagler • 9 Dec 2023

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals